Drug Profile


Alternative Names: 15(S)-HETE; 15(S)-hydroxyeicosatetraenoic acid; 15-HETE; AL-12959; Dry eyes therapy - Alcon; PROCALYX

Latest Information Update: 03 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon
  • Class Antineoplastics; Eye disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Mucin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Dry eyes

Most Recent Events

  • 03 Jul 2007 No development reported - Phase-II for Dry eyes in European Union (unspecified route)
  • 03 Jul 2007 No development reported - Phase-III for Dry eyes in USA (unspecified route)
  • 03 Jul 2007 No development reported - Preclinical for Dry eyes in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top